RAPT Therapeutics, Inc. (NASDAQ:RAPT) Major Shareholder Sells $504,960.59 in Stock

RAPT Therapeutics, Inc. (NASDAQ:RAPT) major shareholder Group Ii Lp Column sold 14,317 shares of the firm’s stock in a transaction that occurred on Monday, September 13th. The shares were sold at an average price of $35.27, for a total transaction of $504,960.59. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Group Ii Lp Column also recently made the following trade(s):

  • On Wednesday, September 15th, Group Ii Lp Column sold 33,535 shares of RAPT Therapeutics stock. The shares were sold at an average price of $37.35, for a total transaction of $1,252,532.25.
  • On Friday, September 10th, Group Ii Lp Column sold 21,738 shares of RAPT Therapeutics stock. The shares were sold at an average price of $35.19, for a total transaction of $764,960.22.
  • On Monday, August 23rd, Group Ii Lp Column sold 68,340 shares of RAPT Therapeutics stock. The shares were sold at an average price of $31.34, for a total transaction of $2,141,775.60.
  • On Friday, August 20th, Group Ii Lp Column sold 4,539 shares of RAPT Therapeutics stock. The stock was sold at an average price of $30.08, for a total transaction of $136,533.12.

Shares of NASDAQ:RAPT opened at $38.83 on Friday. RAPT Therapeutics, Inc. has a 12 month low of $14.63 and a 12 month high of $43.26. The company’s fifty day simple moving average is $32.90 and its 200 day simple moving average is $26.62. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -16.11 and a beta of 0.04.

RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings data on Wednesday, August 11th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.05. RAPT Therapeutics had a negative net margin of 1,219.06% and a negative return on equity of 45.84%. Equities analysts predict that RAPT Therapeutics, Inc. will post -2.64 earnings per share for the current year.

Hedge funds have recently modified their holdings of the business. Royal Bank of Canada increased its stake in RAPT Therapeutics by 89.2% in the 2nd quarter. Royal Bank of Canada now owns 1,230 shares of the company’s stock valued at $39,000 after buying an additional 580 shares during the last quarter. Ameritas Investment Partners Inc. increased its stake in RAPT Therapeutics by 45.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,409 shares of the company’s stock valued at $45,000 after buying an additional 440 shares during the last quarter. Citigroup Inc. increased its stake in RAPT Therapeutics by 99.1% in the 2nd quarter. Citigroup Inc. now owns 2,714 shares of the company’s stock valued at $86,000 after buying an additional 1,351 shares during the last quarter. Legal & General Group Plc increased its stake in RAPT Therapeutics by 27.3% in the 2nd quarter. Legal & General Group Plc now owns 3,047 shares of the company’s stock valued at $96,000 after buying an additional 653 shares during the last quarter. Finally, Metropolitan Life Insurance Co NY acquired a new stake in RAPT Therapeutics in the 2nd quarter valued at $169,000. Hedge funds and other institutional investors own 87.57% of the company’s stock.

RAPT has been the topic of several analyst reports. SVB Leerink initiated coverage on shares of RAPT Therapeutics in a report on Thursday, August 12th. They issued an “outperform” rating and a $49.00 target price on the stock. Cantor Fitzgerald increased their target price on shares of RAPT Therapeutics from $51.00 to $71.00 and gave the stock an “overweight” rating in a report on Monday, June 14th. Piper Sandler initiated coverage on shares of RAPT Therapeutics in a report on Sunday, June 20th. They issued an “overweight” rating and a $61.00 target price on the stock. Wells Fargo & Company increased their target price on shares of RAPT Therapeutics from $30.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, June 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $56.00 target price on shares of RAPT Therapeutics in a report on Monday, August 30th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $59.86.

RAPT Therapeutics Company Profile

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Read More: What is the QQQ ETF?

Insider Buying and Selling by Quarter for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.